Vira-A

NDA 50523, held by Parkedale. Vidarabine.

As of Nov 13, 2026, NDA 50523 (Vira-A), held by Parkedale, was first approved by FDA on Oct 18, 1978, with 0 approved supplements and 0 published complete response letters.

• First approved: Oct 18, 1978
• Review: Priority
• Supplements approved: 0
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters